<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00932698</url>
  </required_header>
  <id_info>
    <org_study_id>C16003</org_study_id>
    <nct_id>NCT00932698</nct_id>
  </id_info>
  <brief_title>Study of Oral IXAZOMIB in Adult Patients With Relapsed and/or Refractory Multiple Myeloma</brief_title>
  <official_title>An Open-Label, Dose-Escalation, Phase 1 Study of the Oral Form of IXAZOMIB (MLN9708), a Second-Generation Proteasome Inhibitor, in Adult Patients With Relapsed and/or Refractory Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Millennium Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Millennium Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will determine the safety profile, tolerability, and maximum tolerated dose (MTD)
      and disease response of IXAZOMIB administered orally in patients with relapsed and/or
      refractory multiple myeloma.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Adverse events (AEs), serious adverse events (SAEs), assessments of clinical laboratory values, neurotoxicity grading, and vital sign measurements</measure>
    <time_frame>From first dose of study drug to 30 days after last dose, upto 13 months</time_frame>
    <description>Safety profile of IXAZOMIB</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To inform the recommended Phase 2 dose of IXAZOMIB</measure>
    <time_frame>12 months</time_frame>
    <description>Phase 2 dose of IXAZOMIB based on both toxicity and efficacy outcomes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Adverse events (AEs), serious adverse events (SAEs), assessments of clinical laboratory values, neurotoxicity grading, and vital sign measurements</measure>
    <time_frame>From first dose of study drug to the end of 21 days Cycle 1</time_frame>
    <description>Tolerability and MTD of IXAZOMIB</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To characterize the pharmacokinetics (PK) parameters, including, but not limited to, Cmax, Tmax, AUC0-last, AUC0-inf, clearance (CL/F), terminal disposition rate constant, and terminal disposition half-life (t1/2)</measure>
    <time_frame>Days 1 and 11 of Cycle 1</time_frame>
    <description>Characterization of PK in plasma of orally administered IXAZOMIB</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To characterize the whole blood 20S proteasome inhibition parameters including, but not limited to, maximum inhibition (Emax) and time of occurrence of Emax (TEmax)</measure>
    <time_frame>Days 1 and 11 of Cycle 1</time_frame>
    <description>Characterization of the pharmacodynamic effect of IXAZOMIB</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the overall response rate (CR+PR) and CR+PR+MR rate</measure>
    <time_frame>At beginning of Cycle 2 (Day 1) and at the end of treatment up to 12 months or until disease progression</time_frame>
    <description>To determine the overall response rate (CR+PR) and CR+PR+MR rate of IXAZOMIB in patients with relapsed and/or refractory multiple myeloma and in patients who are either proteasome inhibitor-na√Øve, have relapsed after VELCADE, or who have recently been treated with carfilzomib</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Relapsed and Refractory Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Arm 1: Oral IXAZOMIB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral IXAZOMIB</intervention_name>
    <description>Phase 1: Patients will be administered IXAZOMIB orally on Days 1, 4, 8, and 11 during a 21-day treatment cycle. Doses will increase until a maximum tolerated dose (MTD) is established.</description>
    <arm_group_label>Arm 1: Oral IXAZOMIB</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Each patient must meet all of the following inclusion criteria to be enrolled in the study:

          -  Multiple myeloma diagnosed according to the standard criteria.

          -  Patients with multiple myeloma who have relapsed following at least 2 lines of
             therapy.

          -  Patients must have measurable disease.

          -  ECOG performance status of 0 to 2.

          -  Female patients who are post menopausal, surgically sterile, or agree to practice 2
             effective methods of contraception or abstain from heterosexual intercourse.

          -  Male patients who agree to practice effective barrier contraception or agree to
             abstain from heterosexual intercourse.

          -  Voluntary written consent.

          -  Suitable venous access for study-required blood sampling.

        Exclusion Criteria:

        Patients meeting any of the following exclusion criteria are not to be enrolled in the
        study:

          -  Peripheral neuropathy &gt; or equal to Grade 2.

          -  Female patients who are lactating or have a positive serum pregnancy test during the
             screening period.

          -  Major surgery within 14 days before the first dose of study drug.

          -  Infection requiring systemic antibiotic therapy or other serious infection within 14
             days before the first dose of study treatment.

          -  Life-threatening illness unrelated to cancer.

          -  Diarrhea &gt; Grade 1, based on the NCI CTCAE categorization.

          -  Systemic antineoplastic or radiation therapy within 14 days of cytotoxic agents within
             21 days before the first dose of study treatment.

          -  Treatment with any investigational products within 21 days before the first dose of
             study treatment.

          -  Treatment with any investigational proteasome inhibitor.

          -  Systemic treatment with prohibited medication.

          -  Ongoing therapy with corticosteroids greater than 10mg of prednisone or its equivalent
             per day. Inhaled and topical steroids are permitted.

          -  Central nervous system involvement.

          -  Evidence of current uncontrolled cardiovascular conditions, including cardiac
             arrhythmias, congestive heart failure, angina, or myocardial infarction within the
             past 6 months.

          -  QTc &gt; 470 milliseconds on a 12-lead ECG obtained during the screening period.

          -  Known human immunodeficiency virus (HIV) positive, hepatitis B surface
             antigen-positive status, or known or suspected active hepatitis C infection.

          -  Any serious medical or psychiatric illness that could, in the investigator's opinion,
             potentially interfere with the completion of treatment according to the protocol.

          -  Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral
             absorption of tolerance of IXAZOMIB including difficulty swallowing.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Millennium Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33617</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Comprehensive Cancer Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M.D. Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 1, 2009</study_first_submitted>
  <study_first_submitted_qc>July 2, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 3, 2009</study_first_posted>
  <last_update_submitted>May 23, 2014</last_update_submitted>
  <last_update_submitted_qc>May 23, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 26, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Relapsed multiple myeloma</keyword>
  <keyword>Refractory multiple myeloma</keyword>
  <keyword>IXAZOMIB Proteasome inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ixazomib</mesh_term>
    <mesh_term>Glycine</mesh_term>
    <mesh_term>Proteasome Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

